Amended Current Report Filing (8-k/a)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 5, 2017

 

 

MELINTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE		001-35405		45-4440364
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
300 George Street, Suite 301, New Haven, CT				06511
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code [phone]

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

---

Introductory Note

This amendment is being filed solely to re-file a signed copy of Exhibit No. 23.1 the Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm to the Current Report on Form 8-K/A filed on December 5, 2017. The signature was inadvertently omitted from the original Exhibit.

 

Item 9.01.

Financial Statements and Exhibits.

 

(a)

Exhibits.

 

Exhibit No.		Description
23.1		Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 6, 2017				Melinta Therapeutics, Inc.
				By:		/s/ Paul Estrem
						Paul Estrem
						Chief Financial Officer